Nasiri Kalmarzi Rasoul, Fattahi Nima, Kaviani Zeinab, Ataee Pedram, Mansouri Majid, Moradi Ghobad, Yousefzade Alireza, Abbassi Javid Morad
Cellular & Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran; Besat Hospital Clinical Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Allergol Int. 2017 Apr;66(2):326-331. doi: 10.1016/j.alit.2016.08.008. Epub 2016 Sep 8.
T-cell response outcome is determined by co-stimulatory/inhibitory signals. Programmed cell death-1 ligand-1 (PD-L1) is a member of these co-signaling molecules with known soluble form in human serum. Soluble PD-L1 (sPD-L1) is also recognized in patients with some types of malignancy or autoimmune disorders, though there are few studies on sPD-L1 roles in allergic diseases. The purpose of this survey was to evaluate the association between sPD-L1 levels with eosinophil count as well as disease severity in allergic rhinitis (AR) patients.
90 patients with AR were selected. Disease severity was determined by a modified Allergic Rhinitis and its Impact on Asthma (ARIA) classification as mild, moderate and severe. Whole blood samples were collected. Then eosinophil count and serum sPD-L1 were detected by a hematologic analyzer and a commercial ELISA kit.
13 (14.44%), 31 (34.44%), and 46 (51.12%) of patients had mild, moderate and severe disease, respectively. The mean levels of sPD-L1 and eosinophil count were ascertained 18.38 ± 14.42 ng/ml and 422.43 ± 262.26 cell/μl. A significant inverse correlation was determined between sPD-L1 levels and eosinophil count (r = -0.364, P < 0.001). Moreover, we detected a significant negative association between sPD-L1 levels and disease severity (r = -0.384, P < 0.001).
It is deduced that sPD-L1 can be used as a helpful marker to determine the severity of AR. Furthermore, this study indicated that sPD-L1 may have an inhibitory role in AR development, and its modulation may be considered as a useful accessory therapeutic approach for reduction of AR progression.
T细胞反应结果由共刺激/抑制信号决定。程序性细胞死亡1配体1（PD-L1）是这些共信号分子中的一员，在人血清中具有已知的可溶性形式。可溶性PD-L1（sPD-L1）在某些类型的恶性肿瘤或自身免疫性疾病患者中也可被检测到，不过关于sPD-L1在过敏性疾病中的作用的研究较少。本调查的目的是评估过敏性鼻炎（AR）患者中sPD-L1水平与嗜酸性粒细胞计数以及疾病严重程度之间的关联。
选取90例AR患者。疾病严重程度通过改良的变应性鼻炎及其对哮喘的影响（ARIA）分类确定为轻度、中度和重度。采集全血样本。然后通过血液分析仪和商用ELISA试剂盒检测嗜酸性粒细胞计数和血清sPD-L1。
分别有13例（14.44%）、31例（34.44%）和46例（51.12%）患者患有轻度、中度和重度疾病。sPD-L1和嗜酸性粒细胞计数的平均水平分别确定为18.38±14.42 ng/ml和422.43±262.26细胞/μl。sPD-L1水平与嗜酸性粒细胞计数之间存在显著负相关（r = -0.364，P < 0.001）。此外，我们检测到sPD-L1水平与疾病严重程度之间存在显著负相关（r = -0.384，P < 0.001）。
推断sPD-L1可作为确定AR严重程度的有用标志物。此外，本研究表明sPD-L1可能在AR发展中具有抑制作用，其调节可被视为减少AR进展的一种有用的辅助治疗方法。
